MTB Real-TM Resistance 8 (Multiplex PCR preamplification and resistance for rifampicine (RIF) and isoniazide (INH) in genes rpoB 531, rpoB 526-1, rpoB 526-2, rpoB 516, rpoB 533, katG 315, inhA 209)
- Known as:
- MTB Real-TM Resistance 8 (Multiplex PCR test kit preamplification resistance rifampicine (RIF) isoniazide (INH) genes rpoB 531, rpoB 526-1, rpoB 526-2, rpoB 516, rpoB 533, katG 315, inhA 209)
- Catalog number:
- B421-50FRT RG, iQ, MX, SC, A
- Product Quantity:
- 50 tests
- Category:
- -
- Supplier:
- Sacace
- Gene target:
- MTB Real- Resistance 8 (Multiplex PCR preamplification and resistance for rifampicine (RIF) isoniazide (INH) genes rpoB 531 526-1 526-2 516 533 katG 315 inhA 209)
Related genes to: MTB Real-TM Resistance 8 (Multiplex PCR preamplification and resistance for rifampicine (RIF) and isoniazide (INH) in genes rpoB 531, rpoB 526-1, rpoB 526-2, rpoB 516, rpoB 533, katG 315, inhA 209)
- Gene:
- ACSF2 NIH gene
- Name:
- acyl-CoA synthetase family member 2
- Previous symbol:
- -
- Synonyms:
- FLJ20920, ACSMW
- Chromosome:
- 17q21.33
- Locus Type:
- gene with protein product
- Date approved:
- 2007-10-17
- Date modifiied:
- 2015-08-26
- Gene:
- ANGPTL8 NIH gene
- Name:
- angiopoietin like 8
- Previous symbol:
- C19orf80
- Synonyms:
- TD26, RIFL
- Chromosome:
- 19p13.2
- Locus Type:
- gene with protein product
- Date approved:
- 2011-08-04
- Date modifiied:
- 2015-11-11
- Gene:
- BDH2 NIH gene
- Name:
- 3-hydroxybutyrate dehydrogenase 2
- Previous symbol:
- DHRS6
- Synonyms:
- UCPA-OR, FLJ13261, UNQ6308, PRO20933, SDR15C1
- Chromosome:
- 4q24
- Locus Type:
- gene with protein product
- Date approved:
- 2005-11-22
- Date modifiied:
- 2016-12-12
- Gene:
- C8orf33 NIH gene
- Name:
- chromosome 8 open reading frame 33
- Previous symbol:
- -
- Synonyms:
- FLJ20989
- Chromosome:
- 8q24.3
- Locus Type:
- gene with protein product
- Date approved:
- 2005-07-19
- Date modifiied:
- 2017-07-12
- Gene:
- CCDC30 NIH gene
- Name:
- coiled-coil domain containing 30
- Previous symbol:
- -
- Synonyms:
- FLJ20972, PFD6L, LOC728621
- Chromosome:
- 1p34.2
- Locus Type:
- gene with protein product
- Date approved:
- 2009-07-09
- Date modifiied:
- 2015-08-24
Related products to: MTB Real-TM Resistance 8 (Multiplex PCR preamplification and resistance for rifampicine (RIF) and isoniazide (INH) in genes rpoB 531, rpoB 526-1, rpoB 526-2, rpoB 516, rpoB 533, katG 315, inhA 209)
Related articles to: MTB Real-TM Resistance 8 (Multiplex PCR preamplification and resistance for rifampicine (RIF) and isoniazide (INH) in genes rpoB 531, rpoB 526-1, rpoB 526-2, rpoB 516, rpoB 533, katG 315, inhA 209)
- Biological exposure indices (BEIs) shape South Korea's special health examination system, yet the epistemological assumptions underpinning their regulatory use have received little scrutiny. In 2023, the American Conference of Governmental Industrial Hygienists (ACGIH) reduced the benzene threshold limit value-time-weighted average (TLV-TWA) from 0.5 to 0.02 ppm, a 25-fold decrease that exposed serious practical limitations in biomarker frameworks for low-level carcinogen monitoring. This narrative review analyzes the ACGIH BEI and DFG (Deutsche Forschungsgemeinschaft) systems using primary sources, with benzene as the paradigm case for structural and operational differences between frameworks. ACGIH and DFG operationalize biological monitoring differently: ACGIH assigns benzene BEI values, whereas DFG declines to set a health-based tolerance value and instead provides exposure-response correlations (EKA) and nonsmoker population reference values (BAR). South Korea's system has structural defects, including the listing of S-phenylmercapturic acid (S-PMA) only as a recommended indicator, while the second-tier options retain confounding-prone biomarkers such as trans,trans-muconic acid (t,t-MA). No currently validated benzene biomarker can reliably monitor compliance at 0.02 ppm. BEIs are exposure assessment tools, not diagnostic thresholds or legal standards. Restoring this distinction requires interpretation within integrated surveillance, evidence-based biomarkers such as S-PMA, and analytical capacity for the 0.02 ppm era. - Source: PubMed
Publication date: 2026/10/07
Kim Yangwoo - Antipsychotic-induced weight gain and metabolic disturbance are common in schizophrenia, but liability varies across agents. Aripiprazole has a relatively favorable metabolic profile, yet evidence on aripiprazole once-monthly, its long-acting injectable formulation, remains limited. We hypothesized that switching from a higher liability antipsychotic would yield a greater weight reduction than switching from a lower liability agent. - Source: PubMed
Publication date: 2026/10/07
Kim SeoyoungLee Kyu YoungChee Hyun SeungChoi JoonhoKim Young-HoonKim Won-HyoungLee Heon-JeongJeong Ji-WoonLee Yu SangPark Il HoKim Jong WooOh Hong SeokKim Moon-DooKim EuitaeKwon Jun Soo - The coronavirus disease 2019 (COVID-19) pandemic disrupted healthcare delivery worldwide, raising concerns about continuity of care for people living with HIV (PLWH). However, its long-term effect on HIV treatment outcomes in resource-rich settings with robust public health infrastructure remains unclear. Therefore, this study aims to evaluate the effects of the COVID-19 pandemic on virological outcomes, immunological status, healthcare utilization, medication adherence, and mortality among PLWH enrolled in the Korea HIV/AIDS Cohort. - Source: PubMed
Publication date: 2026/10/05
Nam EunKyungChoi Jun YongKim Jung HoKim Young KeunKim Sang IlPark Dae WonChoi Won SukLee Jin-SooSong Joon YoungPark BoyoungHong SungheeAhn Kyoung HwanKim Shin-Woo - Connective tissue disease-associated pulmonary hypertension (CTD-PH) comprises subtypes with divergent prognoses, yet its established endpoint, transplant-free survival (TFS), aggregates death and lung transplantation and cannot reveal whether subtypes differ in death, transplantation, or both. We decomposed TFS into its competing components in systemic sclerosis-associated (SSc-PH), systemic lupus erythematosus-associated (SLE-PH), and idiopathic PH (iPH). - Source: PubMed
Publication date: 2026/10/06
Yoon JiyeolLee Sang-WonPark Yong-BeomSong Jason Jungsik - S-scheme heterojunction engineering has emerged as an effective strategy for enhancing photocatalytic NO removal by facilitating charge separation while maintaining strong redox capability. Herein, an S-scheme heterojunction consisting of S-doped TiO2 nanotubes and g-C3N4 was successfully constructed via an annealing-assisted interfacial engineering strategy. Comprehensive band structure analyses using Mott-Schottky measurements, valence band X-ray photoelectron spectroscopy, and Kelvin probe force microscopy confirmed the formation of an S-scheme heterojunction between S-TiO2 and g-C3N4. The experimental results revealed a favorable band alignment and the establishment of an interfacial built-in electric field between S-TiO2 and g-C3N4, facilitating S-scheme charge transfer across the heterointerface and preserving highly reactive electrons and holes with strong reduction and oxidation capabilities, respectively, thereby promoting the generation of ·O2- and ·OH radicals. As a result, the optimized g-C3N4/S-doped TiO2 nanotube photocatalyst achieved an NO removal efficiency of 74.6%, higher than those of pristine S-TiO2 (43.4%) and g-C3N4 (53.4%), while also suppressing NO2 intermediate formation compared with previously reported TiO2- and g-C3N4-based heterojunctions. This work provides insight into the synergistic role of band alignment, interfacial built-in electric field, and S-scheme charge transfer in boosting photocatalytic NO removal performance. - Source: PubMed
Publication date: 2026/10/07
Le Pho ThiBui Thach KhacTran Nhat Quang MinhDoan Tin Chanh DucAnus AliPark SungjinPham Viet Van